EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

Autor: Peter Dreger, Aleksandar Radujkovic, Thomas Luft, Matthias F. Bauer, Felix Korell, Uta Merle, Florentina Kosely, Axel Benner, Lars P. Kihm, Clemens-Martin Wendtner
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
030204 cardiovascular system & hematology
Severity of Illness Index
SARS-CoV2 (COVID- 19)
0302 clinical medicine
soluble thrombomodulin
Clinical endpoint
Immunology and Allergy
Prospective Studies
Prospective cohort study
suppressor of tumorigenicity 2 (ST2)
Original Research
Aged
80 and over
Hazard ratio
Hematopoietic Stem Cell Transplantation
angiopoietin-2 (Ang-2)
Middle Aged
Prognosis
Hospitalization
Treatment Outcome
Cohort
Female
Adult
medicine.medical_specialty
Adolescent
Immunology
prediction of outcome
Young Adult
03 medical and health sciences
Internal medicine
Severity of illness
medicine
Humans
Transplantation
Homologous
Survival analysis
Aged
endothelial activation and stress index
SARS-CoV-2
EASIX
business.industry
COVID-19
Endothelial Cells
Odds ratio
RC581-607
Respiration
Artificial
Survival Analysis
Transplantation
030104 developmental biology
Immunologic diseases. Allergy
business
Biomarkers
Zdroj: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
ISSN: 1664-3224
DOI: 10.3389/fimmu.2021.634416
Popis: BackgroundThe coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19.MethodsSARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions.ResultsEASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, pConclusionEASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
Databáze: OpenAIRE
Externí odkaz: